You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. HUCBC modulation of Alzheimer's-like pathology and behavioral changes

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. MyFAP: A Multimedia Intervention for Adolescents and Young Adults with FAP

    SBC: Radiant Creative Group, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): In this Phase II STTR application, we will build upon work conducted in our successful Phase I project which established the technical merit, acceptability and feasibility of developing a Web-based intervention, MyFAP.org, for adolescents and young adults (AYAs) with familial adenomatous polyposis (FAP). The main research goal of Phase II is to evaluate the eff ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. EGFR Peptides as Vaccines in Anti-Tumor Immunity

    SBC: L2 DIAGNOSTICS LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Epidermal Growth Factor Receptor (EGFR) bearing tumors remain as one of the most insidious and difficult to treat human malignancies, affecting thousands of individuals each year. Our proposed studies are aimed at developing novel tumor immunotherapy by using both cryptic peptides of EGFR protein as well as isoaspartyl modified EGFR peptides, both of which brea ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien

    SBC: MABVAX THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The carbohydrate antigen sialyl-Lewis a (sLea) is widely expressed on epithelial tumors of the gastrointestinal tract, on breast cancer cells, and also on small cell lung cancer cells but is expressed minimally or not at all on normal tissues. sLea serves as a ligand for epithelial leukocyte adhesion molecules and higher expression of sLea was observed in patie ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. User Adaptation of AAC Device Voices

    SBC: BIOSPEECH INC            Topic: NIDCD

    DESCRIPTION (provided by applicant): Augmentative and alternative communication devices with voice output (also known as Speech Generating Devices, or SGDs) enable individuals to speak by electronic means. Typical users of SGDs are individuals who have suffered from a stroke, traumatic brain injury, or who have neurodegenerative or neurodevelopmental disorders. In most cases, the user was able to ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Antimicrobial Dental Devices and Waterlines

    SBC: SELENIUM LTD            Topic: NIDCR

    DESCRIPTION (provided by applicant): Bacterial contamination of dental water lines is a major concern in modern dentistry and may cause infection in dental patients with compromised immune systems. This includes patients with cancer, diabetes, or AIDS; cardiac patients who often require prophylactic antibiotics prior to dental treatment; the elderly, young children, and pregnant women. Bacterial l ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Lactoferrin for Immunomodulation of Systemic Inflammatory Response Syndrome

    SBC: Pharmareview Corporation            Topic: NIGMS

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop a biologic therapeutic to treat systemic inflammatory response syndrome (SIRS) using a novel human recombinant lactoferrin that contains humanized glycosylation patterns. SIRS is a clinical expression of the action of complex acute-phase intrinsic mediators that precedes sepsis and subsequent tissue damage leadin ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Mitochondrial Dysfunction in HAART: Point of Care Tests

    SBC: MITOSCIENCES, INC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious side-effects, including metabolic complications from mitochondrial toxicities that can be life-threatening, and limit effectiveness and patient compliance. Adverse metabolic effects are now managed by adept clinicians who monitor patients closely for clinical symptoms and adjust t ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Multipurpose reversible terminators

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: NHGRI

    DESCRIPTION (provided by applicant): This Phase 2 STTR application will allow the Foundation for Applied Molecular Evolution (FfAME) to complete its transfer of technology to Firebird Biomolecular Sciences LLC, allowing Firebird to commercialize nucleoside triphosphates where the 3'-OH groups are blocked by a 3'-ONH2 group. Triphosphates having this modification are accepted by DNA polymerases and ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  10. An Interactive Informed Consent Program for Cardiac Procedures

    SBC: ARCHIE MD INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Informed consent has become an essential component of the doctor-patient interaction. The informed consent process requires that patients not only be given information about proposed medical treatment, but that it be presented in an understandable way so the patient can make meaningful choices about medical alternatives. At the heart of the informed consent doc ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government